MacroGenics Inc. [NASDAQ: MGNX] closed the trading session at $26.33 on 09/01/20. The day’s price range saw the stock hit a low of $24.69, while the highest price level was $28.82. The company report on August 5, 2020 that MacroGenics to Participate in Upcoming Investor Conferences.
MacroGenics, Inc. (Nasdaq: MGNX), a clinical-stage biopharmaceutical company focused on discovering and developing innovative monoclonal antibody-based therapeutics for the treatment of cancer, today announced that the Company’s management will participate in the following investor conferences in August:.
Webcasts of each presentation may be accessed under “Events & Presentations” in the Investor Relations section of MacroGenics’ website at http://ir.macrogenics.com/events.cfm. The Company will maintain archived replays of these webcasts on its website for 30 days after each conference.
The stocks have a year to date performance of 142.00 percent and weekly performance of -3.69 percent. The stock has been moved at 209.76 percent over the last six months. The stock has performed -1.39 percent around the most recent 30 days and changed 25.32 percent over the most recent 3-months.
If compared to the average trading volume of 753.23K shares, MGNX reached to a volume of 1042673 in the most recent trading day, which is why market watchdogs consider the stock to be active.
Here’s what leading stock market gurus have to say about MacroGenics Inc. [MGNX]:
Based on careful and fact-backed analyses by Wall Street experts, the current consensus on the target price for MGNX shares is $29.00 per share. Analysis on target price and performance of stocks is usually carefully studied by market experts, and the current Wall Street consensus on MGNX stock is a recommendation set at 2.00. This rating represents a strong Buy recommendation, on the scale from 1 to 5, where 5 would mean strong sell, 4 represents Sell, 3 is Hold, and 2 indicates Buy.
Citigroup have made an estimate for MacroGenics Inc. shares, keeping their opinion on the stock as Neutral, with their previous recommendation back on August 03, 2020. The new note on the price target was released on June 01, 2020, representing the official price target for MacroGenics Inc. stock. Previously, the target price had yet another raise from $22 to $40, while H.C. Wainwright kept a Buy rating on MGNX stock.
The Average True Range (ATR) for MacroGenics Inc. is set at 1.78, with the Price to Sales ratio for MGNX stock in the period of the last 12 months amounting to 17.90. The Price to Book ratio for the last quarter was 5.32, with the Price to Cash per share for the same quarter was set at 4.40.
MGNX stock trade performance evaluation
MacroGenics Inc. [MGNX] fell into the red zone at the end of the last week, falling into a negative trend and dropping by -3.69. With this latest performance, MGNX shares dropped by -1.39% in over the last four-week period, additionally plugging by 209.76% over the last 6 months – not to mention a rise of 92.05% in the past year of trading.
Overbought and oversold stocks can be easily traced with the Relative Strength Index (RSI), where an RSI result of over 70 would be overbought, and any rate below 30 would indicate oversold conditions. An RSI rate of 50 would represent a neutral market momentum. The current RSI for MGNX stock in for the last two-week period is set at 46.22, with the RSI for the last a single of trading hit 45.39, and the three-weeks RSI is set at 49.08 for MacroGenics Inc. [MGNX]. The present Moving Average for the last 50 days of trading for this stock 27.57, while it was recorded at 27.26 for the last single week of trading, and 15.85 for the last 200 days.
MacroGenics Inc. [MGNX]: An insightful look at the core fundamentals
Operating Margin for any stock indicates how profitable investing would be, and MacroGenics Inc. [MGNX] shares currently have an operating margin of -276.04. MacroGenics Inc.’s Net Margin is presently recorded at -236.51.
Return on Total Capital for MGNX is now -70.30, given the latest momentum, and Return on Invested Capital for the company is -60.60. Return on Equity for this stock declined to -64.12, with Return on Assets sitting at -47.10. When it comes to the capital structure of this company, MacroGenics Inc. [MGNX] has a Total Debt to Total Equity ratio set at 13.26. Additionally, MGNX Total Debt to Total Capital is recorded at 11.70, with Total Debt to Total Assets ending up at 9.78. Long-Term Debt to Equity for the company is recorded at 11.95, with the Long-Term Debt to Total Capital now at 10.55.
Reflecting on the efficiency of the workforce at the company, MacroGenics Inc. [MGNX] managed to generate an average of -$395,341 per employee. Receivables Turnover for the company is 3.03 with a Total Asset Turnover recorded at a value of 0.20.MacroGenics Inc.’s liquidity data is similarly interesting compelling, with a Quick Ratio of 5.70 and a Current Ratio set at 5.70.
Earnings per share (EPS) analysis for MacroGenics Inc. [MGNX] stock
With the latest financial reports released by the company, MacroGenics Inc. posted -0.91/share EPS, while the average EPS was predicted by analysts to be reported at -0.98/share. When compared, the two values demonstrate that the company surpassed the estimates by a Surprise Factor of 7.10%. The progress of the company may be observed through the prism of EPS growth rate, while Wall Street analysts are focusing on predicting the 5-year EPS growth rate for MGNX.
MacroGenics Inc. [MGNX]: Insider Ownership positions
There are presently around $1,358 million, or 96.30% of MGNX stock, in the hands of institutional investors. The top three institutional holders of MGNX stocks are: BELLEVUE GROUP AG with ownership of 5,002,116, which is approximately -18.255% of the company’s market cap and around 2.10% of the total institutional ownership; RA CAPITAL MANAGEMENT, L.P., holding 4,584,652 shares of the stock with an approximate value of $120.71 million in MGNX stocks shares; and INVESCO LTD., currently with $117.91 million in MGNX stock with ownership of nearly -0.03% of the company’s market capitalization.
Positions in MacroGenics Inc. stocks held by institutional investors increased at the end of July and at the time of the July reporting period, where 81 institutional holders increased their position in MacroGenics Inc. [NASDAQ:MGNX] by around 17,202,221 shares. Additionally, 69 investors decreased positions by around 10,514,642 shares, while 14 investors held positions by with 23,877,476 shares. The mentioned changes placed institutional holdings at 51,594,339 shares, according to the latest SEC report filing. MGNX stock had 39 new institutional investments in for a total of 14,136,978 shares, while 24 institutional investors sold positions of 4,650,474 shares during the same period.